Foundayo Sleep Apnea Results: What the Pill Did in Phase 3

The short answer

Foundayo (orforglipron), Eli Lilly's once-daily GLP-1 pill, cut sleep apnea breathing pauses by 43.8% in adults not using a PAP machine and by 27.5% in adults using one, after 52 weeks in the phase 3 ATTAIN-OSA trials. Lilly announced the results on November 9, 2026. Foundayo is not FDA-approved for sleep apnea yet; Lilly plans to file by the end of 2026, and Zepbound is still the only GLP-1 drug with that approval. People in the trials lost about 28 pounds, so protect your muscle while the weight comes off: Sharpy gives you a daily protein target and a 20-minute workout.

Does Foundayo help sleep apnea? Yes, in two new phase 3 trials. Foundayo (orforglipron) cut the number of breathing pauses during sleep by 43.8% in adults who were not using a PAP machine, and by 27.5% in adults who were, after 52 weeks. Eli Lilly announced the results on November 9, 2026. They were presented at the American Heart Association Scientific Sessions and published in JAMA the same day. Foundayo is not approved for sleep apnea yet. Lilly plans to ask the FDA by the end of 2026.

That makes Foundayo the first GLP-1 pill with positive late-stage results in obstructive sleep apnea (OSA). Here is what the trials showed, what they did not show, and how the pill compares with Zepbound.

What is Foundayo?

Foundayo is the brand name for orforglipron, a once-a-day GLP-1 pill made by Eli Lilly. The FDA approved it on April 1, 2026 for weight management in adults with obesity, or overweight plus a weight-related health problem. It can be taken at any time of day, with or without food. Our Foundayo (orforglipron) guide covers the label, side effects and price in full.

Foundayo sleep apnea results: the ATTAIN-OSA trials

ATTAIN-OSA was really two trials run side by side. Everyone had moderate-to-severe obstructive sleep apnea and obesity or overweight.

  • Study 1: 363 adults who could not or would not use PAP therapy (CPAP and similar machines).
  • Study 2: 349 adults who had used PAP for at least 3 months and kept using it.

People took Foundayo or a placebo pill once a day for 52 weeks. The dose was raised in steps every four weeks to the highest dose each person could handle: 9 mg, 14.5 mg or 17.2 mg.

Doctors grade sleep apnea with the apnea-hypopnea index (AHI). It counts how many times per hour your breathing stops or gets very shallow. An AHI of 15 to 29 is moderate. An AHI of 30 or more is severe. People in these trials started at an average of 50.7 and 57.6, which is well into severe.

Result at 52 weeks Study 1: no PAP, Foundayo Study 1: placebo Study 2: using PAP, Foundayo Study 2: placebo
Starting AHI (average) 50.7 50.7 57.6 57.6
AHI change, events/hour -21.1 -4.3 -18.3 -5.5
AHI change, % -43.8% -6.3% -27.5% -3.0%
Oxygen drop score (hypoxic burden) -55.9% -18.3% -45.8% -17.0%
Body weight change -11.5% (28.0 lb) -1.8% (4.4 lb) -11.2% (28.2 lb) -0.9% (2.2 lb)

Source: Lilly's November 9, 2026 announcement. These numbers assume people stayed on their pill for the full 52 weeks.

Two more results from Lilly's announcement:

  • AHI cut in half or more: 47.2% of people on Foundayo without PAP, and 33.7% of those using PAP.
  • Remission or mild sleep apnea: 31.5% without PAP, and 19.6% with PAP. Remission meant an AHI under 5. Mild meant an AHI of 5 to 14 with no heavy daytime sleepiness.

Foundayo also lowered systolic blood pressure by 8.6 and 7.3 points and cut hsCRP, a marker of inflammation, by 48.9% and 38.6%. Our Foundayo blood pressure guide explains what the label says about blood pressure.

Can Foundayo cure sleep apnea?

For some people, but not most. Do the simple math on the averages. People without PAP started at 50.7 events per hour and dropped by 21.1. That leaves about 30 events per hour, which is still on the line between moderate and severe. About 3 in 10 reached remission or mild disease. About 7 in 10 did not.

So think of Foundayo as something that may make sleep apnea less severe, not as a replacement for treatment. If you use CPAP, keep using it. In Study 2, people stayed on PAP the whole time. Never stop or change your machine settings on your own. Your sleep doctor can order a repeat sleep study after you have lost weight to see what you still need.

Is Foundayo FDA approved for sleep apnea?

No. As of November 11, 2026:

  • Foundayo is approved in the US for weight management only.
  • Lilly says it plans to submit Foundayo to the FDA for moderate-to-severe OSA in adults with obesity or overweight by the end of 2026. Filings in other countries will follow.
  • There is no approval date yet. An FDA review takes months, and approval is never guaranteed.

This matters for insurance. Plans look at the approved uses on the label. Since sleep apnea is not on the Foundayo label today, a sleep apnea diagnosis alone is unlikely to get Foundayo covered right now. A prescriber can still choose it for weight management if you qualify under the current label. That decision belongs to you and your doctor.

Foundayo vs Zepbound for sleep apnea

Zepbound (tirzepatide) is the only GLP-1 medicine with an FDA approval for sleep apnea. It got that approval on December 20, 2024. Retatrutide, another Lilly drug, has trial results but no approval for anything. The three were tested in separate trials, not against each other, so read this table as a rough guide only.

Foundayo (orforglipron) Zepbound (tirzepatide) Retatrutide
How it is taken Pill, once a day Shot, once a week Shot, once a week
Sleep apnea trial ATTAIN-OSA, 52 weeks SURMOUNT-OSA, 52 weeks TRIUMPH-1-OSA, 80 weeks
AHI change, events/hour -18.3 to -21.1 -25.3 to -29.3 -25.7 to -36.1
AHI change on placebo -4.3 to -5.5 -5.3 to -5.5 -11.1
Body weight change About -11% About -18% to -20% -14.0% to -23.4%
Approved for sleep apnea? No. Filing planned by end of 2026 Yes, since December 2024 No. Not approved for any use

The pattern is clear. The drugs that took off more weight also cut more breathing pauses. Foundayo's edge is that it is a pill with no food or water rules. For the approved option, see our Zepbound for sleep apnea guide. For the newest shot data, see our retatrutide sleep apnea guide.

How does a GLP-1 pill help sleep apnea?

Obstructive sleep apnea happens when soft tissue in the throat collapses during sleep and blocks air. Extra fat around the neck, tongue and belly makes that more likely. When weight comes off, the airway has more room. That is why the benefit builds over months, not on the first night. The FDA said the same thing about Zepbound: the improvement is likely tied to the weight lost.

Here is the catch. People in ATTAIN-OSA lost about 28 pounds. Fast weight loss can take muscle along with fat, and muscle is what keeps you strong and helps you hold the loss later. Sharpy is built for this part. It gives you one daily protein target, one 20-minute strength workout and one Shape Score, so you can see if the weight you lose is mostly fat. Our protein target on GLP-1 guide shows how the number is set.

Side effects in the sleep apnea trials

Lilly says the safety picture matched earlier Foundayo trials. The most common side effects were stomach and gut problems: nausea, diarrhea, constipation, indigestion and vomiting. Most were mild to moderate.

More people quit Foundayo because of side effects than quit placebo:

Stopped because of side effects Foundayo Placebo
Study 1 (no PAP) 12.2% 3.8%
Study 2 (using PAP) 6.8% 0.6%

Like other GLP-1 drugs, Foundayo carries a boxed warning about thyroid C-cell tumors. People with a personal or family history of medullary thyroid cancer or MEN 2 should not take it. If you are pregnant, planning to be, or under 18, talk with your doctor first.

What to do now if you have sleep apnea

  • Keep your current treatment. CPAP works from the first night. No pill does that.
  • Get a real diagnosis. If you snore loudly, wake up gasping or feel sleepy all day, ask your doctor about a sleep study.
  • Ask about approved options. If you have obesity and moderate-to-severe OSA, Zepbound is approved for that today. Your doctor can tell you if it fits.
  • Do not chase unapproved versions. Only FDA-approved Foundayo from a licensed pharmacy has been checked for quality.
  • Protect your sleep and your muscle. Our GLP-1 and sleep guide covers habits that help.

The bottom line

Foundayo is the first GLP-1 pill to show it can make obstructive sleep apnea less severe in phase 3 trials. Breathing pauses fell by 43.8% without PAP and 27.5% with PAP, and people lost about 11% of their body weight. It is not approved for sleep apnea yet, most people still had sleep apnea after a year, and CPAP stays the standard treatment. If weight loss is part of your sleep apnea plan, make it fat loss. Sharpy keeps your protein target, your 20-minute workout and your Shape Score in one place.

Sources

Questions people ask

Does Foundayo help with sleep apnea?

In two phase 3 trials, yes. In ATTAIN-OSA, Foundayo lowered the apnea-hypopnea index (AHI) by 21.1 events per hour (43.8%) in adults not using PAP therapy, versus 4.3 events per hour on placebo. In adults using PAP, it lowered AHI by 18.3 events per hour (27.5%), versus 5.5 on placebo. Both trials ran 52 weeks.

Is Foundayo FDA approved for sleep apnea?

No. As of November 11, 2026, Foundayo is approved in the US only for weight management in adults with obesity, or overweight with a weight-related health problem. Lilly says it plans to submit Foundayo to the FDA for moderate-to-severe obstructive sleep apnea by the end of 2026.

Is there a GLP-1 pill for sleep apnea?

Not an approved one yet. Foundayo is the first GLP-1 pill with positive phase 3 sleep apnea results, but it does not have that approval. The only GLP-1 medicine approved for obstructive sleep apnea today is Zepbound, a weekly shot.

Foundayo vs Zepbound for sleep apnea: which worked better?

They have not been tested head to head. In separate one-year trials, Zepbound lowered AHI by 25.3 to 29.3 events per hour and Foundayo lowered it by 18.3 to 21.1. People also lost more weight on Zepbound (about 18% to 20%) than on Foundayo (about 11%). Zepbound is approved for sleep apnea; Foundayo is not.

Can Foundayo cure sleep apnea?

Not for most people in the trials. After a year, 31.5% of people on Foundayo without PAP and 19.6% of those using PAP reached remission or mild sleep apnea. That means most people still had moderate or severe sleep apnea. Only a repeat sleep study can show where you stand.

Can I stop CPAP if I take Foundayo?

Do not stop or change CPAP on your own. One of the two trials enrolled people who kept using PAP the whole time, and Foundayo was studied on top of it. Your sleep doctor decides if and when a new sleep study makes sense.

What were the side effects of Foundayo in the sleep apnea trials?

Lilly says the most common were stomach-related: nausea, diarrhea, constipation, indigestion and vomiting, mostly mild to moderate. More people stopped Foundayo because of side effects than stopped placebo: 12.2% versus 3.8% in the trial without PAP, and 6.8% versus 0.6% in the trial with PAP.

Read next